Overview

Efficacy and Safety of Orally Administered DS102 in Patients With Acute Alcoholic Hepatitis

Status:
Suspended
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this randomised, double-blind, placebo-controlled, phase II study is to assess the efficacy and safety of orally administered DS102 in patients with acute decompensated alcoholic hepatitis
Phase:
Phase 2
Details
Lead Sponsor:
Afimmune